Orano Med’s Post

📣 We are excited to join the #oncology community at #ASCO24!   #OranoMed and its partner Radiomedix, Inc. are thrilled and honored to announce that results from our Phase 2 study with 212Pb-DOTAMTATE (AlphaMedix™) have been accepted for oral presentation at the ASCO Annual Meeting in Chicago. Join us to discover our latest advancements presented by Prof. Jonathan Strosberg (Moffitt Cancer Center, Tampa/FL) during the rapid oral abstract session on Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary. 📅 Monday, June 3rd, 2024 | 10:57 AM CT “Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.” Abstract: #4020 (https://lnkd.in/gtNYY2jy) We are very much looking forward to sharing these results, that also contributed to the recent FDA Breakthrough Therapy designation. #ASCO2024 #Oncology #AlphaTherapy #MedicalInnovation #CancerResearch #Radiopharmaceuticals #FutureOfMedicine

📣 We are excited to join the #oncology community at #ASCO24!   #OranoMed and its partner Radiomedix, Inc. are thrilled and honored to announce that results from our Phase 2 study with 212Pb-DOTAMTATE (AlphaMedix™) have been accepted for oral presentation at the ASCO Annual Meeting in Chicago. Join us to discover our latest advancements presented by Prof. Jonathan Strosberg (Moffitt Cancer Center, Tampa/FL) during the rapid oral abstract session on Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary. 📅 Monday, June 3rd, 2024 | 10:57 AM CT “Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.” Abstract: #4020 (https://lnkd.in/exHPyeSX) We are very much looking forward to sharing these results, that also contributed to the recent FDA Breakthrough Therapy designation. #ASCO2024 #Oncology #AlphaTherapy #MedicalInnovation #CancerResearch #Radiopharmaceuticals #FutureOfMedicine

Exciting Progress as ALX Oncology's Phase II ASPEN-06 clinical trial has unveiled positive topline data for evorpacept, a CD47-blocking drug, in treating HER2-positive gastric cancer. When combined with standard therapies, evorpacept has shown a marked improvement in tumour response rates. This could be a game-changer for patients battling this aggressive cancer ✅ The trial included 127 patients previously treated with an anti-HER2 agent, assessing the effectiveness of evorpacept with trastuzumab, CYRAMZA, and paclitaxel (TRP) compared to just TRP 🥼 Highlights from study findings: ✔️Enhanced Tumour Response Rates**: Evorpacept group achieved a 40.3% ORR vs. 26.6% in the TRP-only group. ✔️Improved Duration of Response**: Median response duration extended to 15.7 months with evorpacept, compared to 7.6 months in the control group. ✔️Specifically Effective in HER2-positive Biopsies**: Achieved an impressive 54.8% ORR among patients with fresh HER2-positive biopsies. The significance of these findings cannot be overstated. Evorpacept's potential to enhance clinical outcomes in HER2-positive gastric cancer opens doors for further exploration in other tumour types. #ALXOncology #CancerResearch #OncologyResearch #Oncology #ClinicalTrials #ClinicalResearch #LifeScience #ElixirAssociates #StaffingPartner

This month is #EsophagealCancer Awareness Month 🌎 🩺 Check out this NEW interview from #ASCOGI 2024 | NIVO + #chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649 🎥 Kohei Shitara, MD, National Cancer Center Hospital East, presents the 4-year follow-up results of the Phase III #CheckMate649 (NCT02872116) trial, evaluating #nivolumab in combination with #chemotherapy (chemo) versus #chemo alone in previously untreated, advanced non-#HER2+ #gastriccancer/#gastroesophagealjunction/#esophageal #adenocarcinoma (GC/GEJC/EAC) 🔦 The study, which demonstrated superior overall survival (OS) and progression-free survival (PFS) benefits with #nivolumab + #chemo, continues to show efficacy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 5 🔬 #Nivolumab + #chemo maintains a favorable safety profile, making it the first PD-1 inhibitor/chemo combination to exhibit long-term efficacy and safety after 4 years in this patient population ✅ Take a look 👉 https://lnkd.in/e7DMi7aB #Oncology #Oncologynews #EsophagealCancerAwarenessMonth American Society of Clinical Oncology (ASCO)

We are attending the #ESMOGI24 congress. 👨⚕️ This congress provides an opportunity to share the latest scientific and medical advances in the field of gastrointestinal cancers. At Servier, we aim to be a focused and innovative player in oncology. Each year, we invest over 70% of our 🔬R&D budget to oncology, particularly to developing treatments for hard-to-treat cancers.  We look forward to seeing you at our booth – N° 2 - and our symposiums: 📌 June 27 - 12:45 - 1:45 pm (CEST) - “Perspectives on the Current and Future Management of mCRC: Consensus and Controversies” 📌 June 27 - 6:15 - 7:15 pm (CEST) - “Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey” - PeerVoice CME CCA Industry Satellite Symposium supported by Servier, Incyte and Taiho Oncology, Inc. 📌 June 28 - 1:15 - 2:15 pm (CEST) - “Pathways to Enhance Patients’ Benefits in Metastatic Pancreatic Cancer” Learn more about Servier’s commitments 👉 https://swll.to/U8TPQUD #GICancer #GastroIntestinalcancers #oncology #gastroenterology ESMO - European Society for Medical Oncology

🚨 The development of a promising new cancer treatment has hit a snag due to a shortage of a critical radioactive isotope. BMS, which recently acquired RayzeBio for $4.1 billion, has paused enrollment of new patients in the Phase 3 trial of the radiopharmaceutical agent RYZ101. The experimental treatment is being tested for neuroendocrine tumors. The company expects new patient enrollment to restart in the third quarter of this year and anticipates being able to "support ongoing clinical supply" by the first quarter of 2024. BMS is also conducting a separate Phase 1b trial of RYZ101 in small cell lung cancer patients, still screening new participants. Actinium-225, the specific isotope used in RYZ101, is exceedingly rare, which has long been a concern for developers of actinium-based radiopharmaceuticals. 💔 #HealthcareNews #CancerResearch #MedicalInnovation #Radiotherapy #ClinicalTrials #BMS #RayzeBio #IsotopeShortage #MedicalBreakthrough #HealthUpdates #Oncology #CancerTreatment

Check out this new study! Our PredicineCARE™ cfDNA assay was utilized in the poster presentation from NorthShore University Health System on day 1 of ASCO GU!    A prospective study of comprehensive genomic testing to identify actionable variants in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)      In this study, PredicineCARE™ cfDNA assay, as well as in-house tissue and germline tests, was employed for comprehensive genomic testing to identify potentially actionable variants for an FDA-approved PARP inhibitor treatment in metastatic castration-resistant prostate cancer (mCRPC). The data shows about 38% of patients had one or more variants with a recommendation for an on-label treatment.    The results demonstrated that PredicineCARE™ cfDNA assay provided more actionable variants, 14 of 19 BRCA1/2 variants in this cohort detected by cfDNA only!    Connect with Predicine at Predicine Booth #24 and explore our innovative liquid biopsy solutions that support global clinical trials, companion diagnostics development, and commercialization. Schedule a personal meeting with the Predicine experts: https://lnkd.in/dTJ9tkAu    Learn more about PredicineCARE™ assay:   https://lnkd.in/g7rgW2qB    #ASCOGU24 #precisiononcology #diagnostics #NGS #liquidbiopsy #mrd #ctdna

+++ 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗹𝗮𝘁𝗲𝘀𝘁 𝗱𝗮𝘁𝗮 𝗮𝘁 𝘁𝗵𝗲 𝗗𝗚𝗛𝗢 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟰 +++ In just four days, this year's DGHO Congress (Annual Congress of the German, Austrian and Swiss Societies of Haematology and Oncology) will take place in Basel. This year, we will present our latest data in seven posters and four oral presentations: 𝗦𝘂𝗻𝗱𝗮𝘆, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟯 8:45-9:00 Centralized vs. decentralized testing for PD-L1 and HER2 in patients with metastatic gastric and esophageal cancer – Results from the German research platform SAPHIR. (V519) 𝗠𝗼𝗻𝗱𝗮𝘆, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟰 10:00-10:15 First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: Interim results of the prospective CARAT registry, 2024 (V938) 10:00-11:30 Das weite Feld der Dosis – zwischen studien-generierter maximaler therapeutischer Dosis und „optimaler biologischer Dosis“ aus real-world Daten (V926) 12:45-13:00 Treatment reality and outcomes of patients with intermediate, locally advanced or metastatic hepatocellular cancer – Results from the prospective national intersectoral cohort study JADE (V1004) We look forward to seeing you in Basel! #DGHO #RWD #Realworlddata #Realwordevidence #oncology

Dr Federico Cappuzzo & David Planchard joined us at ESMO 2024 to share their insights into new non-small cell lung cancer data presented at the congress. 📺 Watch the video to get their key takeaways and hear how they think these developments could impact clinical practice 👇 The experts review data from several key trials: ➡️ Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant mNSCLC. Riely G, et al. (Abstract LBA56) ➡️ Encorafenib plus binimetinib in patients with previously untreated BRAF V600E-mutant advanced NSCLC: an open-label, multicenter phase 2 trial (IFCT-1904 ENCO-BRAF). Planchard D, et al. (Abstract 1259MO) ➡️ First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E-mutant metastatic NSCLC. Di Federico A, et al. (Abstract 1299P) ➡️ Phase 2 trial of vemurafenib and cobimetinib in BRAF V600-mutated solid tumours and first-Line NSCLC: Australian Molecular Screening and Therapeutics (MoST) Substudy 12 Lin F, et al. (Abstract 623P) Supported by an Independent Education Grant from Pierre Fabre. This content is not intended for HCPs within the UK. #MedicalEducation #Oncology

For US #HCPs: in Annals of Oncology, authors Drs. Enriqueta Felip & Se-Hoon Lee report a subgroup analysis of patients with features of high-risk disease in the Phase 3 MARIPOSA study of EGFRxMET bispecific antibody + 3rd-gen TKI in first-line EGFR-mutant advanced non-small cell #LungCancer.